KVP Capital Advisors, LP
KVP Capital Advisors, LP reported 35 US-listed holdings worth $136.2 million in its 13F for the quarter ended 30 June 2026, filed 13 August 2026. Its largest: Praxis Precision Medicines I (10.5%), Aadi Bioscience Inc. (7.3%) and Erasca Inc. (6.1%). Against the quarter before, it opened 6 positions, added to 2, trimmed 2 and sold out of 3.
The 14 largest of its 35 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +34.3% over the 2 quarters to 30 June 2026, against +9.5% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 6
- Tandem Diabetes Care Inc. TNDM$4.5 million
- Arrivent Biopharma Inc. AVBP$3.5 million
- Design Therapeutics Inc. DSGN$2.7 million
- Mineralys Therapeutics Inc. MLYS$2.3 million
- Artiva Biotherapeutics Inc. ARTV$1.9 million
- Evolus Inc. EOLS$1.0 million
Added to 2
- Erasca Inc. ERAS+115,000 shares · +34%
- Compass Therapeutics Inc. CMPX+271,000 shares · +54%
Trimmed 2
- Axsome Therapeutics, Inc. AXSM-24,200 shares · -67%
- Travere Therapeutics, Inc. TVTX-52,000 shares · -57%
Sold out of 3
- Terns Pharmaceuticals Inc. TERN$23.2 million last quarter
- Revolution Medicines, Inc. RVMD$3.9 million last quarter
- Soleno Therapeutics Inc. SLNO$2.0 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Praxis Precision Medicines I PRAX | 42.9K | $14.4 million | 10.54% | no change |
| Aadi Bioscience Inc. WHWK | 2.2M | $9.9 million | 7.28% | no change |
| Erasca Inc. ERAS | 455.0K | $8.3 million | 6.12% | +115.0K |
| Trevi Therapeutics Inc. TRVI | 414.0K | $7.7 million | 5.67% | no change |
| Sutro Biopharma Inc. STRO | 226.6K | $7.5 million | 5.52% | no change |
| Tango Therapeutics, Inc. TNGX | 230.3K | $7.2 million | 5.28% | no change |
| MBX Biosciences Inc. MBX | 121.5K | $6.7 million | 4.92% | no change |
| Protagonist Therapeutics, Inc. PTGX | 53.0K | $6.5 million | 4.77% | no change |
| Edgewise Therapeutics Inc. EWTX | 133.0K | $5.4 million | 3.97% | no change |
| Tandem Diabetes Care Inc. TNDM | 301.0K | $4.5 million | 3.33% | new |
| Disc Medicine Inc. IRON | 58.2K | $4.3 million | 3.13% | no change |
| Savara Inc. SVRA | 605.3K | $3.7 million | 2.74% | no change |
| Arrivent Biopharma Inc. AVBP | 102.0K | $3.5 million | 2.60% | new |
| Insmed Inc. INSM | 28.5K | $3.0 million | 2.23% | no change |
| Achieve Life Sciences Inc. ACHV | 462.4K | $3.0 million | 2.22% | no change |
| Ideaya Biosciences, Inc. IDYA | 79.7K | $3.0 million | 2.18% | no change |
| Ocular Therapeutix Inc. OCUL | 300.0K | $2.9 million | 2.16% | no change |
| Axsome Therapeutics, Inc. AXSM | 12.0K | $2.9 million | 2.16% | -24.2K |
| Design Therapeutics Inc. DSGN | 185.0K | $2.7 million | 1.96% | new |
| United Therapeutics Corp. UTHR | 4.8K | $2.6 million | 1.89% | no change |
| Scholar Rock Holding Corp. SRRK | 45.0K | $2.5 million | 1.82% | no change |
| Immix Biopharma Inc. IMMX | 230.4K | $2.4 million | 1.74% | no change |
| Viridian Therapeutics, Inc. VRDN | 125.0K | $2.3 million | 1.69% | no change |
| Mineralys Therapeutics Inc. MLYS | 84.2K | $2.3 million | 1.67% | new |
| Bright Minds Biosciences Inc. DRUG | 31.8K | $2.2 million | 1.64% | no change |
| Travere Therapeutics, Inc. TVTX | 39.0K | $2.2 million | 1.63% | -52.0K |
| Zura Bio Ltd ZURA | 373.1K | $2.2 million | 1.62% | no change |
| Artiva Biotherapeutics Inc. ARTV | 200.0K | $1.9 million | 1.42% | new |
| Nektar Therapeutics NKTR | 26.9K | $1.9 million | 1.38% | no change |
| Compass Therapeutics Inc. CMPX | 771.0K | $1.7 million | 1.24% | +271.0K |
| Cabaletta Bio Inc. CABA | 505.4K | $1.6 million | 1.15% | no change |
| Vera Therapeutics Inc. VERA | 32.7K | $1.4 million | 1.03% | no change |
| Evolus Inc. EOLS | 150.0K | $1.0 million | 0.76% | new |
| Celcuity Inc. CELC | 4.0K | $418,480 | 0.31% | no change |
| Vyne Therapeutics Inc. VYNE | 500.6K | $325,709 | 0.24% | no change |